# Phase 1 trial: 52% of KRAS G12D mutation lung cancer patients saw tumors shrink - Date: 2026-04-20 - Category: Biotech & Life Sciences Half the patients in a Phase 1 trial saw their tumors shrink after failing two prior therapies. Zoldonrasib earned the first FDA Breakthrough Therapy Designation ever for the KRAS G12D mutation, and its median PFS of 11.1 months doubles what earlier KRAS drugs managed. ---